Uresil

Executive Summary

Uresil, founded in 1978 and headquartered in Skokie, Illinois, is a privately held medical device company specializing in minimally invasive fluid drainage and specialty catheter products. With over four decades of experience, the company serves interventional radiology, surgery, and emergency care markets, focusing on innovative solutions that improve patient outcomes and reduce healthcare costs. Uresil's portfolio includes high-quality devices designed for safety and efficacy in critical procedures, positioning it as a trusted partner for healthcare providers. As a mature, bootstrapped company, Uresil's growth strategy likely revolves around product line expansions and incremental innovation rather than venture-backed disruption. Its competitive advantage lies in its specialized niche and long-standing reputation for quality. However, limited public information on financials and pipeline makes near-term visibility challenging. The company may benefit from increasing demand for minimally invasive procedures and value-based care trends. While no specific catalysts are publicly known, potential events could include FDA clearances for next-generation drainage catheters or strategic partnerships to expand distribution.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance for New Catheter Platform60% success
• Q4 2026Expansion into International Markets via Distributor Agreements50% success
• TBDLaunch of Next-Generation Drainage System with Antimicrobial Coating55% success